Kinomica

📢 We are thrilled to welcome Richard Arnatt to the Kinomica team as our new Head of Product Development! In the course of developing products at Cyted Health and Siemens, Rich has amassed experience in diagnostics and data analytics, clinical data management, digital delivery platforms and laboratory automation that uniquely qualifies him for this crucial role. In his own words: “The confluence of phosphoproteomics and data analytics underpinning Kinomica's ground-breaking technology is phenomenally powerful. I am extremely excited about making it available for patients who don't have time to waste finding the right therapy. It feels as if all my previous roles were in preparation for this singular task and I am thrilled to be joining my new Kinomica colleagues to help make it a reality.” Welcome to the team Rich! #welcome #newhire #teamwork #kinomica

If you missed the MAP 2024 conference, here's some of our highlights 👇 💉 MAP 2024 nicely summarised recent discoveries in precision medicine, technologies for cancer profiling, and biomarker-driven development of targeted therapeutics. But it omitted advances in proteomics - where there has been notable progress. We would welcome the opportunity to showcase this next year! 🤖 Important topics/challenges discussed in this session included: ethical and privacy concerns; integration with current IT-systems; data availability; what is appropriate clinical validation; and the extent of user guidance/ training required for proper-use. All big challenges as AI rapidly approaches the clinic 🗺️ The programme nicely built up to the ‘RoadMAP to the clinic’ session, which focused on new AI-based developments and their implementation in clinical practice. The main take home was that while there are some great exemplars of AI in the clinic, it’s important to support its success with the necessary infrastructure Congratulations to ESMO - European Society for Medical Oncology for putting on such an inspiring event, full of discussions and guidance on the use of AI for drug development and clinical practice. We look forward to returning next year! Photo credit - MAP2024 #MAP2024 #precisionmedicine #diagnostics #clinicaltrials #clinicaloncology #AI #kinomica

The Kinomica team are popping down to London for MAP 2024 this week 🚆 The focus of ESMO - European Society for Medical Oncology's Molecular Analysis for Precision Oncology Congress this year is the use of AI for drug development/precision medicine, looking into the challenges of deploying AI at scale, tackling regulatory and ethical aspects of AI implementation in clinical trials, and examining the opportunities and challenges of AI for research and practice. Arran Dokal is looking forward to discussing these challenges with experts in the field, meeting new collaborators, and identifying areas where our KScan® technology could make a difference. Want to find out more about KScan® - our phosphoproteomic platform? Comment below to arrange a meeting 👇 We look forward to seeing you in London! #MAP2024 #precisionmedicine #diagnostics #clinicaltrials #clinicaloncology #AI #kinomica

📢 Summer is over and we're back with some exciting new updates. One of them is welcoming Krystyna Sykes to the Kinomica team! Krystyna is our new Clinical Samples Acquisition Manager, and joins us with a wealth of drug discovery, clinical trials, and biosamples management experience gained in big pharma and biotech. In her own words: ”Having worked in the oncology space for many years, I know how important it is to select the right therapy for patients first time. That is why I am so excited to be joining Kinomica. The highly predictive phosphoproteomic diagnostics being developed by the team have the potential to significantly aid clinical decision-making.” Welcome to the team Krystyna! #welcome #newhire #teamwork #kinomica

We combined mass spectrometry phosphoproteomics with machine learning to predict the response to midostaurin combined with chemotherapy in acute myeloid leukaemia. Now our findings have been published in The Lancet's eBioMedicine! Here's what we found 👇 When we applied our phosphoproteomic stratification methods to 2 independent retrospective real-world patient test cohorts, we found it greatly outperformed the current 𝘍𝘓𝘛3 status-based stratification method for midostaurin combined with intensive chemotherapy (MIC) treatment. Arran Dokal, CTO of Kinomica says "This work has wide-ranging implication in AML and beyond. For AML, the predictive model presented can be used to better identify patients that would benefit from MIC treatment, and could have utility for patients who are currently ineligible for MIC treatment due to lack of mutations in 𝘍𝘓𝘛3." Read the paper 👉 https://lnkd.in/eJxx7jg4 Find out more in our press release 👉 https://lnkd.in/eipf849n #precisionmedicine #diagnostics #machinelearning #clinicaloncology #biomarkers #massspectometry #cancerresearch #lancet #ebiomedicine #kinomica

We're #hiring a new Senior Scientist in Macclesfield, England. Apply today or share this post with your network.

If you missed the 72nd American Society For Mass Spectrometry (ASMS) conference this year, here's some of our highlights 👇 💬 The Kinomica team had a terrific time at ASMS, revelling in highly informative presentations and engaging discussions with some of the world’s leading companies and academics from across the Mass Spectrometry spectrum - forgive the pun! 🪧 Our six posters highlighting Kinomica’s KScan® workflow and its application in clinical proteomics generated a great deal of interest, particularly how we are developing phosphoproteomic diagnostics to aid clinical decision-making and therapy selection in order to improve patient outcomes. ✨ As always, the quality of work on show and the organisation of the conference was exceptional and made the whole experience intellectually stimulating and exciting. Congratulations to ASMS for hosting such an inspiring event, bringing together mass spectrometry vendors, experts, and users from around the world, and helping forge connections and collaborations that will impact the landscape of the technology. We look forward to returning next year! #ASMS24 #precisionmedicine #diagnostics #clinicaloncology #biomarkers #massspectometry #AML #kinomica

If you missed the American Society of Clinical Oncology (ASCO) annual meeting this year, here's some of our highlights 👇 🪧 The Kinomica team want to thank everyone that took the time to engage with us over the last week. We were blown away by the response to our poster presentations! Our updates in AML & HCC were both well-received and we look forward to being able to validate our findings further with such strong clinician engagement. 🩻 Following our demonstration of the technology in HCC, it was fantastic to engage with new clinicians that treat other solid tumours and start exploring the potential that KScan has to improve patient outcomes in other cancers with large unmet clinical needs. ✨ It was wonderful to see the all innovation on show - such a breadth of ideas to help realise the promise of personalised medicine. Truly embracing the theme: “The Art and Science of Cancer Care: From Comfort to Cure”. Congratulations to ASCO for hosting such an inspiring event, bringing together oncology professionals from around the world and helping forge connections and collaborations that will impact the landscape of cancer care. We look forward to returning next year! #ASCO24 #precisionmedicine #diagnostics #clinicaloncology #AML #HCC #kinomica

David Perkins, Amy Campbell and Andrew Williamson presented three Kinomica posters today at #ASMS2024

If you're wondering what we're bringing to American Society For Mass Spectrometry (ASMS) 2024, check out our press release which details the six posters we're taking to Anaheim! Our work will be exhibited from the 3-6 June, showcasing multiple elements of our KScan® platform. Arran Dokal, CTO of Kinomica says "It's well accepted that quantitative phosphoproteomics provides unique biological information that is not captured by other technologies, but any clinical utilization of the technology has been considered challenging. The data we are presenting at ASMS, coupled with the development of predictive signatures for first-line therapies in leukemia and hepatocellular cancer, show the challenges can be overcome and highlight the clinical potential of phosphoproteomics." Tim Fell, Executive Chair of Kinomica says "The breadth and depth of data accepted for presentation at this year's ASMS meeting underline our expertise and dedication to developing clinical proteomics for precision medicine." Read the press release 👉 https://lnkd.in/enjyEDST #ASMS24 #precisionmedicine #diagnostics #clinicaloncology #biomarkers #masspectometry #AML #kinomica